Trademarks registered and published for opposition with USPTO in Class 3 – cosmetics and cleaning Preps, and Class 5 –pharmaceuticals. Marks for vitamin, mineral and supplement products also are registered or published for opposition in both Class 3 and Class 5.

In his first speech to agency staff, Acting Commissioner Norman Sharpless says FDA will continue working on issues including food safety and nutrition drug, and he is not approaching the post like a temporary caretaker. Sharpless said his appointment does not reflect attempt by President Trump or HHS Secretary Alex Azar to force FDA to change direction set by Scott Gottlieb.

Tylenol brand consumption grows 10% on sales of Rapid Release Gel and Tylenol Arthritis, reaching top spot among analgesic products in the US, J&J says. Retailers' inventory builds as a result of prior-year supply constraints driven by Hurricane Maria also helped drive growth.

Tylenol brand consumption grows 10% on sales of Rapid Release Gel and Tylenol Arthritis, reaching top spot among analgesic products in the US, J&J says. Retailers' inventory builds as a result of prior-year supply constraints driven by Hurricane Maria also helped drive growth.

The Cosmetic Ingredient Review Expert Panel is taking its first look at brown algae-derived ingredients, with 32 passing muster at the panel’s April 8-9 meeting in Washington. Salicylic acid and fatty acids were among ingredients that received final safe verdicts, while four ingredient groups drew insufficient data announcements. Finally, parabens got tabled and MCI/MI was reopened for updates.

Governor Andrew Cuomo’s Consumer Right to Know Act, New York’s answer to Prop 65 in California, was scuttled by legislators in their budget bill signed into law April 12. However, related talks are ongoing in the state’s legislature, where the Safe Cosmetics Act is on the table again this session.

Fluocaril and Parogencyl are “well-known” toothpastes that have garnered “strong endorsement from health professionals,” Unilever says. The brands, identified by analysts as potential candidates for sale, are latest in P&G’s ongoing trimming of lower-selling lines.

Annals of Medicine study finds at least 1,000mg/day calcium supplementation associated with increased risk of cancer, but no association of cancer and high levels of calcium from foods. Natural Products Association says study included an ‘unhealthy’ cohort of patients.

Trademarks registered and published for opposition with USPTO in Class 3 – cosmetics and cleaning Preps, and Class 5 –pharmaceuticals. Marks for vitamin, mineral and supplement products also are registered or published for opposition in both Class 3 and Class 5.

FDA extends sunscreen proposed rule comment period; American Kratom Association AKA webinar counters ‘incorrect’ headlines; ProBiora promotes brand with comic book; and Allulose labeling draft guidance includes enforcement discretion.

Six warnings to firms marketing products containing DMHA mark a change in the agency's supplement market oversight with explanation that non-dietary ingredients that have not been approved for use in food are deemed unsafe and are not allowed for use in supplements under an exemption for food additives Other three firms FDA warned were advised the ingredient phenibut found in their products also isn't eligible for use in supplements.

FDA announces addition of Dietary Supplement Ingredient Advisory List page to its website along with recent warning letters to firms marketing supplements containing two ingredients on the list: eight were warned about using ingredient identified as "DMHA" in products, and three about using phenibut. Brand names and product marketers linked to ingredients the FDA deems ineligible for use could be published through other agency channels.

Consumers need more support to help them accurately interpret nutrition and health claims made on foods, including food supplements, a study across five EU markets suggests. Nutrition claims and health claims are regularly confused by consumers, and their technical wording often means they are misunderstood or not understood at all.

The European Medicines Agency is right now looking into how real-world data and evidence can be used to improve regulatory systems and extend access to OTC medicines within the European Union, the agency's executive director Guido Rasi told the recent AESGP Regulatory Conference in Amsterdam.